Patients with high-risk, relapsed or refractory Hodgkin lymphoma, those with systemic anaplastic large-cell lymphoma, and those with primary cutaneous CD30-positive disorders are in need of novel therapies. CD30, a common marker in these malignancies, is a reasonable immunologic target given its restricted expression in normal states. SGN-30 is a chimeric antibody targeting CD30.
Clinical Professor of Medicine, Geffen School of Medicine at UCLA, Director, UCLA Lymphoma Program, 10945 Le Conte Avenue, Suite 2333, Los Angeles, CA 90095, USA. lpinterbrown@mednet.ucla.edu
